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 1 
Abstract 
 
The present study examined whether the inhibition of serotonin transporters (SERT) 
contributes to cocaine- and other local anesthetics-induced convulsions, and which subtypes of 
5-HT receptor are involved in the convulsions. For this purpose, cocaine, meprylcaine and 
lidocaine, all of which have different effects on SERT, were used as convulsants and the effects 
of serotonin reuptake inhibitors (SSRIs), specific agonists and antagonists for 5-HT receptor 
subtypes were evaluated in mice. 
Administration of SSRI, zimelidine, citalopram and fluoxetine, 5-HT2A,2C receptor agonist, 
R(-)-DOI and the 5-HT2C receptor agonists, mCPP and MK212 resulted in a marked increase in 
incidence of convulsions and a reduction in the threshold of lidocaine-induced convulsions, 
while the 5-HT2B receptor agonist, BW723C86, had little influence. On the other hand, SSRI did 
not affect the measured parameters in meprylcaine- and cocaine-induced convulsions.  
R(-)-DOI, mCPP and MK212 reduced the threshold of meprylcaine or cocaine with less extent 
than the reduction of lidocaine threshold. Incidence of cocaine- and meprylcaine-induced 
convulsions were significantly reduced by 5-HT2A,2B,2C antagonist, LY-53857 and 5-HT2C 
antagonist, RS 102221. The threshold of cocaine and meprylcaine was significantly increased 
by both antagonists. 5-HT2A antagonists MDL-11,939 and ketanserin, and 5-HT2B antagonist 
SB-204741 except at high doses had little effect on cocaine- and meprylcaine-induced 
convulsions. None of these antagonists altered the parameters of lidocaine-induced convulsions. 
Pretreatment with fluoxetine but not citalopram increased the plasma concentration of lidocaine. 
These results suggest that the increase of serotonergic neuronal activity through 5-HT2C receptor 
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stimulation was responsible for increased activity of local anesthetics-induced convulsions and 
support the involvement of this mechanism in cocaine- and meprylcaine- but not in lidocaine- 
induced convulsions through their direct inhibitory action on central SERT. 
 
Theme: Neurotransmitters, modulators, transporters, and receptors 
 
Topic: Uptake and transporters 
Keywords: Serotonin transporter; Convulsion; SSRI; Cocaine; Local anesthetics. 
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1. Introduction 
Cocaine and synthetic local anesthetics produce stimulation of central nervous systems at 
toxic doses as observed in seizures both in rodents and humans. It has been generally accepted 
that seizures induced by cocaine and local anesthetics are related to the inhibition of central 
inhibitory nervous systems such as GABAergic and other inhibitory neurons due to their 
blockade of Na+ current , thereby stimulating excitatory neuronal activity [6]. 
Although changes in susceptibility to seizures induced by cocaine and local anesthetics have 
been related to altered brain monoaminergic functions, they are not always uniform [6]. The 
norepinephrine (NE) system does not appear to modulate the proconvulsant effect of cocaine 
[14, 19] or is anticonvulsant to cocaine [17] but it dose enhance synthetic local 
anesthetic-induced convulsions [37]. Cocaine-induced convulsions are controlled positively and 
negatively by dopamine (DA) D1 and D2 receptor stimulation, respectively [30], while the 
involvement of dopaminergic activity is minor in lidocaine-induced convulsions [2, 37]. 
It has been suggested that the manipulation of serotonergic activity significantly modifies 
cocaine-induced seizures. Co-administration of cocaine with fenfluramine racemer, which 
increases synaptic serotonin (5-HT) levels, increased the occurrence and decreased the time of 
onset in status epileptics, without affecting lethality [26]. In addition, the occurrence and 
severity of cocaine-induced convulsions were increased by the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine [20, 24]. Other SSRIs such as citalopram, paroxetine and tricyclic 
antidepressant imipramine also facilitated cocaine-induced convulsions [20]. On the contrary, 
5-HT2 receptor antagonists antagonized cocaine-induced convulsions [21, 24, 26]. An increase 
in brain content of 5-HT also intensified convulsions by local anesthetics, and a decrease in 
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brain 5-HT content increased the threshold [1, 4, 5]. These results are consistent with the idea 
that an increase in serotonergic neuronal activity facilitates convulsive activity of both cocaine 
and local anesthetics. 
Cocaine is known to inhibit monoamine neurotransmitter transporters, including 5-HT 
transporters (SERT). Therefore, the accumulation of 5-HT in the synapse due to the inhibition of 
SERT by cocaine could be involved in the increase in serotonergic neuronal activity. However, 
it could be also possible that cocaine indirectly activates the neurons through cocaine-induced 
inhibition of Na+ current of inhibitory neurons innervating to 5-HT neurons.  
While synthetic local anesthetics are generally believed to lack the effect on monoamine 
transporters, certain local anesthetics have been shown to have cocaine-like reinforcing effects 
in animals [9, 15, 35, 36]. We and others have recently demonstrated that some synthetic local 
anesthetics such as procaine and meprylcaine do inhibit monoamine transporters (MAT) in rat 
brain synaptosomes [36], in COS cells transfected with MAT cDNAs [25] and in SH-SY5Y 
human neuroblastoma cells [16], while lidocaine displays no inhibitory action [25, 34].  
Using local anesthetics as convulsants, all of which have different effects on MAT, 
including cocaine which is a potent inhibitor of MAT, meprylcaine with a relatively potent 
inhibitory effect on MAT and lidocaine, and a typical local anesthetic that does not inhibit MAT 
[25], the present study further examined the role of 5-HT on seizure development; 1) the 
intrinsic role of the inhibition of SERT in the development of seizures was examined by 
comparing the effects of SSRIs which may substitute some pharmacological properties of 
cocaine and the agonists and antagonists for 5-HT receptors on convulsions induced by cocaine, 
meprylcaine and lidocaine, 2) receptor subtypes of 5-HT involved in the development of 
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convulsions induced by these local anesthetics were analyzed using specific agonists and 
antagonists for 5-HT receptor subtypes. 
 
2. Materials and methods 
 
2.1. Animals 
 
Male ICR mice 6 ~ 7 weeks old (25 ~ 35 g) were used. All procedures and handling of 
animals were performed according to the guideline “Guiding Principles for the Care and Use of 
Laboratory Animals” approved by The Japanese Pharmacological Society as well as the 
guideline of Hiroshima University.  
 
2.2. Treatments with drugs  
 
The full chemical names and the supplier were as follows: BW723C86 
[1-[5-(2-thienylmethoxy)-1H-3-indolyl]propan-2-amine hydrochloride; Tocris Cookson, Bristol, 
UK], cocaine hydrochloride (Takeda Pharmaceutical Co. Ltd., Osaka Japan), R(-)-DOI 
[(R)-(-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride; Sigma-Aldrich, St. 
Louis, MO], MK212 [6-chloro-2-(1-piperazinyl)pyrazine hydrochloride; Tocris Cookson], SB 
204741 [N-(1-methyl-5-indolyl)-N’-(3-methyl-5-isothiazolyl) urea; Tocris Cookson], ketanserin 
tartrate [3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]-2,4[1H,3H]-quinazolinedione tartrate; Tocris 
Cookson], mCPP [1-(3-chlorophenyl)piperazine hydrochloride; Tocris Cookson], LY-53,857 
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[6-methyl-1-(1-methylethyl)-ergoline-8β-carboxylic acid 2-hydroxy-1-methylpropyl ester 
maleate; Sigma-RBI], MDL 11,939 [α-phenyl-1-(2-phenylethyl)-4-piperidinemethanol; Tocris 
Cookson], RS 102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl- 
5-oxopentyl)-1,3,8-triazaspiro[4,5]decane-2,4-dione hydrochloride; Tocris Cookson]. 
SB 204741 was dissolved in DMSO and diluted as required in saline (final concentration of 
DMSO was less than 1 %). Other drugs were dissolved in saline. The doses of drugs were 
chosen based upon their functional selectivity at a particular 5-HT2 receptor the affinity profile 
for each of the 5-HT2 receptor ligands [18]. 
 
2.3. Seizures 
 
Mice were intraperitoneally injected with convulsants and placed individually in plastic 
cages for observation of seizure activity. Seizures induced by drugs were characterized by ataxia, 
short loss of the righting reflex and clonic and tonic convulsions. The percent age of animals 
that exhibited convulsions in each treatment group was determined in the 15 min following the 
injection of convulsants. The convulsions were scored as, 1= weak, intermittent chronic 
convulsion; 2= typical clonic convulsion lasting more than 1 min; 3= clonic and tonic 
convulsion with increased locomotor activity or jumping. Thirty minutes after the injection 
of SSIR, 5-HT2 receptor agonists, antagonists or an equal volume of saline, the mice 
were challenged with lidocaine, meprylcaine or cocaine. Percent incidence of the 
appearance of convulsions was determined from the proportion of the number of mice having 
intermittent chronic convulsions (score 1) to the number of mice used. To determine the 
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threshold for lidocaine-, meprylcaine-, and cocaine-induced convulsions, the occurrence of 
clonic convulsion (score 1) was measured by infusing lidocaine solution (4.0 mg/ml), 
meprylcaine solution (2.0 mg/ml), or cocaine solution (2.0 mg/ml) into a tail vein at a rate of 
0.21 ml/min via a 24 gauge butterfly needle attached to a syringe pump and the dosage 
administered was calculated per body weight. Preparation of drug solution, intraperitoneal 
injection or intravenous infusion of the drug into mice and the observation of behavior were 
performed by different persons with blind.  
 
2.3. Statistical analysis 
 
One-side Fisher’s exact probability test was applied for the frequency of the seizures. 
Dunnett’s multiple range test and Welch test were used to calculate the differences in seizure 
severity and seizure threshold, respectively. 
 
2.5. Measurement of plasma lidocaine concentrations 
 
Blood was obtained by cardiopuncture, mixed with 6 mM EGTA and centrifuged at 2500 
rpm for 10 min, and 0.5 ml of plasma was used for solid phase extraction. C18 cartridges (360 
mg/cartridge) were preconditioned by 6 ml of acetonitrile, followed by 6 ml of water. 25 μl of 
working standard solution containing 500 ng of phenacemide, an internal standard (I.S.), was 
added to 0.5 ml of plasma, which was then diluted to 2 ml with HPLC water. The sample was 
transferred onto the preconditioned C18 cartridge. A low vacuum was used to maintain the 
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extraction speed at ~ 0.5 ml/min. After loading the samples, the cartridge was washed four times, 
each time with 1.5 ml of washing solution consisting of acetonitrile-pH 9.0 of phosphate buffer 
(10:90 v/v). The washing speed was also adjusted to ~ 0.5 ml/min. At the end of washing, a high 
vacuum was applied so as to remove the remaining solvent. The washed cartridge was eluted 
with 2.5 ml of acetonitrile-pH 4.0 phosphate buffer (40:60 v/v) at ~ 0.5 ml/min. At the end of 
elution, high vacuum was again applied to recover all the eluting solution. After the vortex, 50 
μl of the effluent was injected onto the column for quantitation.  
Chromatographic conditions 
The mobile phase was acetonitrile-pH 5.9 phosphate buffer (0.05 M) (20:80 v/v), which 
was degassed prior to use and delivered at a flow rate of 1.0 ml/min. The mobile phase was 
prepared from LC-grade solvents. The UV detection was carried out at 210 nm. 
Chromatography was carried out using a conventional HPLC system consisting of a PU-980 
intelligent HPLC pump (Jasco, Tokyo Japan), an autosampler fitted with 100-μl sample loop 
(AS-950-10 intelligent sampler, Jasco), a reversed phase analytical column (Silica rod column, 
C18, Chromolith perfomance RP-18, 100 x 4.6 mm, MERCK), UV-970 intelligent UV/VIS 
detector (Jasco), an integrator (Jasco/JMBS HSS-900, Jasco), and a data processor (BORWIN, 
Jasco).  
 
3. RESULTS 
 
3.1 Effect of SSRIs on convulsions induced by lidocaine and cocaine  
Pretreatments of zimelidine, citalopram, and fluoxetine at 3 ~ 20 mg/kg dose-dependently 
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increased the incidence of convulsions induced by 40 mg/kg of lidocaine and decreased the 
threshold of the convulsions (Table 1). The severity of lidocaine convulsions as evaluated by an 
increase in score of the convulsions was increased by SSRI (scores of convulsions induced by 
lidocaine, lidocaine + zimelidine 20 mg/kg and lidocaine + citalopram 10 mg/kg were 1.0, 2.8 ± 
0.3 and 2.4 ± 0.3, respectively). Zimelidine and citalopram at 20 mg/kg did not affect on the 
incidence of meprylcaine- and cocaine-induced convulsions and did not reduce their threshold at 
10 and 20 mg/kg. Score of cocaine convulsions was not affect by citalopram (scores of 
convulsions induced by cocaine and cocaine + citalopram 10 mg/kg were 2.4 ± 0.3 and 2.9 ± 0.1, 
respectively). 
 
3.2. Effect of 5-HT2 receptor agonists on convulsions induced by lidocaine and cocaine  
 
5-HT2A, 2C receptor agonists, R(-)-DOI at 0.1 mg/kg significantly increased the incidence of 
convulsions induced by lidocaine and reduced the threshold of the convulsions at 0.03, 0.1 and 
1 mg/kg (Table 2). 5-HT2B receptor agonist, BW723C86 had no influence on the incidence and 
the threshold of lidocaine convulsions at 2 and 5 mg/kg and significantly reduced the threshold 
at 5 mg/kg. 5-HT2C receptor agonist, mCPP and MK212 at 1 and 10 mg/kg increased the 
incidence. mCPP at 1 ~ 10 mg/kg and MK212 at 0.1 ~ 10 mg/kg produced a profound reduction 
of the threshold of lidocaine convulsions. The effects were dose-dependent and the threshold 
was reduced to 66.4 % and 35.2 % of the control by mCPP and MK212 at 10 mg/kg, 
respectively. Score of lidocaine convulsions was increased by mCPP and MK212 (scores of 
convulsions induced by lidocaine, lidocaine + mCPP 10 mg/kg and lidocaine + MK212 10 
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mg/kg were 1.0, 3.0 and 3.0, respectively). Threshold of meprylcaine-induced convulsions was 
reduced significantly by R(-)-DOI at 0.1 mg/kg, mCPP at 10 mg/kg and MK212 at 10 mg/kg. 
mCPP at 1 and 10 mg/kg and MK212 at 10 mg/kg significantly reduced threshold of 
cocaine-induced convulsions. The extent of the reduction by these agonists in threshold of 
convulsions induced by meprylcaine and cocaine was much less than that of lidocaine. None of 
the agonists had influence on incidence of meprylcaine- and cocaine-induced convulsions. 
 
3.3 Effect of 5-HT2 receptor antagonists on convulsions induced by cocaine, meprylcaine, and 
lidocaine 
 
Incidence of cocaine-induced convulsions was significantly reduced by 5-HT2A,2B,2C 
antagonist, LY-53857 at 5 mg/kg and 5-HT2C antagonist, RS 102221 at 2 mg/kg (Table 3). The 
threshold of convulsions induced by cocaine was dose-dependently increased by LY-53857 and 
RS 102221 at 1 ~ 5 mg/kg. 5-HT2A antagonists MDL 11,939 and ketanserin except at 3 mg/kg 
and 5-HT2B antagonist SB204741 had no influence on the parameters of cocaine convulsions. 
Incidence of meprylcaine-induced convulsions was also significantly reduced by LY-53857 at 5 
mg/kg and RS 102221 at 2 mg/kg and the threshold was increased by both agents. Ketanserin, 
except at 3 mg/kg, MDL 11,939 and SB204741 had no influence on the parameters of 
meprylcaine convulsions. None of LY-53857, RS 102221, MDL 11,939, ketanserin and 
SB204741 at any dose examined altered the incidence or threshold of lidocaine-induced 
convulsions, while enhancement by citalopram of parameters of convulsion activity of lidocaine 
was antagonized by RS 102221.  
 11 
 3.4. Effect of SSRI treatment on blood levels of lidocaine 
 
Effects of the treatment with citaroplam and fluoxetine on plasma concentration of lidocaine 
was investigated (Fig. 1). The onset time of convulsions after injection of 40 mg/kg was 4.02 ± 
0.35 min in the absence of citalopram. Times were 3.53 ± 0.30 min and 1.82 ± 0.24 min in the 
presence of 10 and 20 mg/kg of citalopram, respectively. A similar onset time was observed 
with fluoxetine. Thus, the plasma concentration immediately before or during convulsions (3 
min or 5 min after injection of lidocaine) was determined. Pretreatment with 10 and 20 mg/kg of 
citalopram had no effect on the concentration of plasma lidocaine after injection of lidocaine at 
3 min. With pre-treatment of fluoxetine at 10 and 20 mg/kg, plasma concentration of lidocaine 
was 189 % and 360 % higher than the control at 3 and 5 min, respectively, after the injection of 
lidocaine. 
  
4. Discussion 
 
Local anesthetics activate limbic discharge, which is most pronounced in the amygdaloid 
nuclear complex [28, 31, 32], though they inhibit nerve conductance primarily by blocking Na+ 
channels. It is recognized that these seizures are due to selective suppression of inhibitory 
neurons such as γ-aminobutyric acid (GABA) in vivo because the firing rate of GABAergic 
neurons is high and local anesthetics-induced inhibition of nerve conductance tend to be 
frequency-dependent [3, 12, 13, 29]. Therefore, GABA mimetic drugs such as benzodiazepins, 
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barbiturates, GABAA receptor agonists and inhibitors of GABA transaminase [7] effectively 
block local-anesthetic-induced seizures. However, cocaine-induced seizures tend to be resistant 
to standard anticonvulsant therapies, including benzodiazepines, barbiturates, and phenytoin [7, 
10, 33]. Convulsions induced by cocaine and synthetic local anesthetics also display different 
features. Certain symptoms of cocaine-induced seizures, including high locomotor activity, 
jumping and tonic-convulsion were not observed in lidocaine-induced seizures. Some 
pharmacological effects of cocaine are due to the inhibition of monoamine re-uptake. 
Convulsions induced by lidocaine together with SSRIs or 5-HT2 receptor agonists displayed 
these three symptoms, as reflected in the increased score of lidocaine convulsions. Therefore, 
the increase of serotonergic activity not only increases the incidence of local 
anesthetics-induced convulsions, but also intensifies the symptoms. However, fluoxetine has an 
inhibitory action on various cytochrome p450 isoenzymes [11]. Therefore, fluoxetine could 
affects the metabolism of lidocaine. This is shown by an increase in plasma concentration of 
lidocaine in combination with fluoxetine in the present study. Fluoxetine-treated rats had higher 
brain levels of cocaine [8]. Citalopram has marginal inhibitory effect on CYP2D6 [27], but did 
not affect on brain cocaine level [8] or plasma lidocaine level at the present study. There is no 
evidence of drug interaction of zimelidine. Thus, the results of fluoxetine should be undervalued. 
The threshold of convulsions induced by cocaine and meprylcaine which have inhibitory action on 
SERT was reduced only slightly by 5-HT2 agonists and was hardly affected by SSRI while these 
agents produced a marked increase in incidence and a profound reduction of the threshold of 
convulsions induced by lidocaine which has no inhibitory action on SERT. The evidence suggests 
that the serotonergic neuronal activity was stimulated by cocaine or meprylcaine themselves and 
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thus 5-HT2 agonists and SSRI had a weak effect on cocaine- and meprylcaine-induced convulsions 
or rare at all. The increase in serotonergic activity could be resulted from the inhibition of SERT 
by cocaine and meprylcaine and/or from the inhibition of inhibitory interneuronal input to 
serotonergic neurons by their blocking action of Na+ channels. However, the latter possibility 
seems not probable, because convulsions induced by lidocaine were not blocked by 5-HT2 
antagonists while convulsions induced by cocaine and meprylcaine were antagonized by 5-HT2 
antagonists nevertheless all of three compounds have common feature of potent inhibitor of Na+ 
channels. Therefore, it is suggested that the activation of serotonergic neurons by cocaine or 
meprylcaine is due to direct inhibition of SERT on the serotonergic neurons. 
Moreover, the density of 5-HT receptors mediates sensitivity to the convulsant effect of 
cocaine across different strains of mice: cinanserin, a 5-HT2 antagonist, more potently attenuates 
cocaine-induced convulsions in C57BL/6J (6J) mice, exhibiting a lower density of 5-HT2 
receptors in the amygdaloid ridge, hypothalamus and midbrain relative to C57BL/6ByJ(6ByJ) 
mice [22]. 5-HT2c agonists, mCPP, MK212, and the SSRI fluoxetine more strongly potentiated 
cocaine-induced convulsions in 6ByJ mice than in 6J mice [23]. The present results show that 
mCPP and MK212 increased the convulsive activity of lidocaine, and at lesser extent. of 
meprylcaine and cocaine. 5-HT2A,2C agonist, R(-)-DOI also increased the convulsive activity of 
lidocaine and little affected on convulsive activity of meprylcaine and cocaine. Futhermore, 
relatively specific antagonists for 5-HT2 receptor subtypes, 5-HT2A,2B,2c antagonist, LY-53,857, 
and 5-HT2c antagonist, RS 102221, reduced the incidence of cocaine- and meprylcaine-induced 
convulsions and increased the threshold. 5-HT2B agonist, BW723C86 and 5-HT2A antagonists, 
ketanserin and MDL 11,939, or 5-HT2B antagonist, SB204741 had no or little influence on the 
 14 
convulsive activity of all of convulsants. These results are consistent with the conclusion that 
5-HT2C sites, appear to be sites involved in cocaine- and meprylcaine-induced convulsions [24]. 
Effectiveness of 5-HT receptor antagonists in blocking cocaine- and meprylcaine-convulsions is 
also suggested. 
In summary, the present study suggested that the increase in serotonergic neuronal activity 
had profound potentiation of local anesthetics-induced convulsion as shown with marked 
facilitation of lidocaine-induced convulsions by SSRI and 5-HT2C agonists. Serotonergic 
neuronal activity was stimulated by cocaine and meprylcaine but not by lidocaine through the 
inhibition of SERT and this mechanism is involved in the convulsion activity of cocaine and 
meprylcaine. Comparing the effects of specific agonists and antagonists for 5-HT receptors on 
convulsions induced by lidocaine, meprylcaine and cocaine, stimulation of post synaptic 5-HT2C 
contributes to intense convulsions of cocaine and meprylcaine. 
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Figure legend 
 
Fig.1. Effects of citalopram and fluoxatine on plasma concentration of lidocaine in mice. 
Lidocaine at 40 mg/kg was injected intraperitoneally 30 min after the injection of citalopram, 
fluoxetine or saline. Blood sample was taken by cardiopuncture in vials containing EGTA at 3 
and 5 min after the injection of lidocaine, and was serum separated and kept at –80°C for 
lidocaine assay. *Significantly different from control, p<0.001, n=4-16. 
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Table 1. Effects of selective serotonin uptake inhibitors on seizure activity induced by lidocaine, 
meprylcaine and cocaine in mice 
Addition mg/kg  % Incidence N1  Thresholda)  
(mg/kg i.v.) 
N2
Lidocaine (40 mg/kg i.p.)-induced convulsion   
Saline   6.7 15 25.12 ± 0.33 13 
Zimelidine 3 (i.p.)   22.65 ± 0.74** 10 
 10 (i.p.)  50.0*  10 19.90 ± 0.71*** 10 
 20 (i.p.)  60.0**  10 18.75 ± 0.56*** 10 
Saline   10.0 20 25.06 ± 0.69 16 
Citalopram 3 (i.p.)  33.3 12 18.64 ± 0.61*** 10 
 10 (i.p.)  66.7*** 15 13.92 ± 0.59*** 11 
 20 (i.p.)  93.3*** 15 12.61 ± 0.77*** 10 
Saline   10.5 19 25.61 ± 0.47 10 
Fluoxetine 5 (s.c.)  30.0 10 19.63 ± 0.52*** 10 
 10 (s.c.)  80.0*** 10 15.96 ± 0.53*** 10 
 20 (s.c.)  88.9***  9   
Meprylcaine (85 mg/kg i.p.)-induced convulsion   
Saline   40.0 10 12.05 ± 0.78  7 
Zimelidine 10 (i.p.)    12.64 ± 0.54  7 
 20 (i.p.)  50.0 10 11.78 ± 0.59  7 
Citalopram 10 (i.p.)    11.64 ± 0.70  7 
 20 (i.p.)  70.0 10 11.48 ± 0.55  7 
Cocaine (50 mg/kg i.p.)-induced convulsion   
Saline   53.3 15 12.55 ± 0.27 15 
Zimelidine 10 (i.p.)    12.88 ± 0.23  7 
 20 (i.p.)  50.0  12.79 ± 0.74  7 
Citalopram 10 (i.p.)  70.0 10 12.94 ± 0.28 10 
 20 (i.p.)  75.0 12 12.60 ± 0.25 10 
One-sided Fisher’s exact probability test was used for seizure susceptibility: *p<0.05,  
** p<0.01, *** p<0.001 vs. saline. a)Data are expressed as the mean ± S.E.M. of the 
threshold for lidocaine- or cocaine-induced convulsions in mice. The Welch test was used 
for the convulsion threshold, ** p<0.01, *** p<0.001 vs. saline. N1, number of mice used; 
N2, number of mice used. 
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Table 2. Effects of 5-HT2 receptor agonists on seizure activities of lidocaine, 
meprylcaine and cocaine in mice 
Pretreatments 
(mg/kg i.p.) 
 % Incidence N1 Convulsive threshold a)
(mg/kg i.v.) 
N2
Lidocaine (40 mg/kg i.p.)-induced convulsion   
Saline   13.3 15 25.13 ± 0.37 14 
R(-)-DOI (0.01)    23.91 ± 1.21 8 
 (0.03)    20.51 ± 0.83*** 8 
 (0.1)  80.0** 10 15.07 ± 0.93*** 8 
Saline   13.3 15 25.12 + 0.33 13 
BW723C86 (2)  14.3 7 24.00 ± 0.55 10 
 (5)  16.7 12 23.89 ± 0.24* 7 
Saline   6.7 15 24.61 ± 0.35 17 
mCPP (1)  50.0* 12 19.66 ± 0.64*** 10 
 (3)    17.41 ± 0.77*** 10 
 (10)  100.0*** 25 16.33 ± 0.27*** 15 
Saline   6.7 15 23.92 ± 0.41 15 
MK212 (0.1)    19.44 ± 0.49*** 10 
 (1)  58.3** 12 14.66 ± 0.46*** 10 
 (10)  100.0*** 10 8.66 ± 0.49*** 8 
Meprylcaine (85 mg/kg i.p.)-induced convulsion   
Saline   40.0 10 13.18 ± 0.54 10 
R(-)-DOI (0.03)    11.84 ± 0.62 7 
 (0.1)  60.0 10 9.68 ± 0.21*** 7 
BW723C86 (5)  30.0 10 14.14 ± 0.31 7 
mCPP (1)    13.50 ± 0.87 7 
 (10)  50.0 10 11.76 ± 0.34* 7 
MK212 (1)    13.31 ± 0.61 7 
 (10)  60.0 10 11.27 ± 0.25** 7 
Cocaine (50 mg/kg i.p.)-induced convulsion   
Saline   60.0 10 12.12 ± 0.39 10 
R-(-)-DOI (0.03)    13.32 ± 0.58 7 
 (0.1)  60.0 10 12.16 ± 0.20 8 
BW723C86 (5)  50.0 10 11.49 ± 0.14 7 
Saline   53.3 15 12.71 ± 0.19 20 
mCPP (1)    10.40 ± 0.41*** 10 
 (10)  50.0 12 11.64 ± 0.23** 10 
MK212 (1)    12.79 ± 0.22 10 
 (10)  66.7 12 11.42 ± 0.23*** 10 
One-sided Fisher’s exact probability test was used for seizure susceptibility: * p<0.05, ** 
p<0.01, *** p<0.001 vs. saline. a)Data are expressed as the mean ± S.E.M. of the 
threshold for lidocaine- or cocaine-induced convulsions in mice. The Welch test was used 
for the convulsion threshold, * p<0.05, ** p<0.01, *** p<0.001 vs. saline. N1, number of 
mice used; N2, number of mice used.
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Table 3. Effects of 5-HT2 receptor antagonists on seizure activities of cocaine, meprylcaine and 
lidocaine in mice 
Convulsants 
(mg/kg i.p.) 
Pretreatments 
(mg/kg i.p.) 
% Incidence N1  Thresholda)
(mg/kg i.v.) 
N2
Cocaine (50)       
 Saline  80.0 15  12.37 ± 0.30 14
 LY-53,857  (0.1)    12.15 ± 0.77 7
  (1)    14.68 ± 0.33*** 7
  (5) 25.0** 16  19.53 ± 0.38*** 13
 Saline  73.3 15  12.41 ± 0.25 14
 RS 102221  (0.3)    13.56 ± 0.65 7
  (1)    14.90 ± 0.60** 7
  (2) 23.5** 17  19.63 ± 0.60*** 13
  (5)    16.98 ± 0.26*** 8
 Saline  53.3 15  12.50 ± 0.21 15
 MDL 11,939  (0.5)    13.54 ± 0.63 7
  (2) 50.0 12  12.42 ± 0.42 10
  (5)    12.96 ± 0.40 7
  (10)    13.27 ± 0.43 7
 Ketanserin  (0.3)    13.43 ± 0.58 7
  (1) 66.7 12  12.38 ± 0.37 10
  (3) 50.0 10  15.03 ± 0.44*** 8
 SB204741  (0.3)    12.53 ± 0.41 7
  (2) 58.3 12  12.58 ± 0.27 10
  (5)    12.21 ± 0.67 7
Meprylcaine (90)      
 Saline  73.3  15  13.15 ± 0.34 13
 LY-53,857 (5) 10.0** 10  20.82 ± 0.41*** 13
 RS 102221  (2) 20.0* 10  19.43 ± 0.40*** 13
 Saline  70.0 10  12.16 ± 0.37 10
 MDL 11,939  (2) 50.0 10  12.50 ± 0.37 7
 Ketanserin  (3) 60.0 10  13.90 ± 0.56* 7
 SB204741 (2) 70.0 10  12.38 ± 0.77 7
Lidocaine (60)      
 Saline  86.7  15  23.00 ± 0.36 18
 LY-53,857 (5) 100.0  10  23.36 ± 0.52 13
 RS 102221  (2) 90.0 10  22.37 ± 0.58 13
 Saline  80.0 10  23.51 ± 0.48 18
 Ketanserin  (3) 80.0 10  23.46 ± 0.61 10
 SB204741 (2) 80.0 10  22.75 ± 0.52 10
 Saline  80.0 10  24.63 ± 0.69 10
 MDL 11,939  (2) 90.0 10  24.88 ± 0.71 8
Lidocaine (40)      
 Saline  6.7  15  25.06 ± 0.69 16
 Citalopram  (10) 66.7*** 15  13.92 ± 0.59*** 11
 Citalopram  
+ RS 102221  
(10) 
(2) 
10.0##  10  21.01 ± 0.38### 13
One-sided Fisher’s exact probability test was used for seizure susceptibility: * p<0.05, 
** p<0.01, *** p<0.001 vs. saline; ## p<0.01 vs citalopram. a)Data are expressed as 
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the mean ± S.E.M. of the threshold for cocaine-, meprylcaine- or lidocaine- induced 
convulsions in mice.  The Welch test was used for the convulsion threshold, * 
p<0.05, ** p<0.01, *** p<0.001 vs. saline; ### p<0.001 vs. citalopram. N1, number of 
mice used; N2, number of mice used.  
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